Vanda Pharmaceuticals' Innovation Reducing Side Effects of Wegovy

Vanda Pharmaceuticals' Clinical Study on Wegovy

A Phase 2 clinical study conducted by Vanda Pharmaceuticals (VNDA) has shown that the company's oral treatment method tradipitant reduces side effects in patients using Novo Nordisk's (NVO) GLP-1 based weight loss drug Wegovy (semaglutide).

Details of the Clinical Study

The study included 116 participants. Participants were given 85 mg of tradipitant or a placebo twice a day starting one week before Wegovy injection. In the following week, participants continued to receive either tradipitant or placebo in conjunction with Wegovy treatment.

Results and Observations

According to the main findings of the study, 58.6% of the participants in the placebo group reported nausea, whereas this rate dropped to 29.3% in the tradipitant group. Additionally, the proportion of those reporting vomiting and nausea in the placebo group was 48.3%, while it fell to 22.4% in the group taking tradipitant. These findings highlight the efficacy and safety of Vanda's tradipitant medication.

Future Goals

Vanda Pharmaceuticals announced plans to advance the clinical testing of this drug to Phase 3 in the first half of 2026. This phase is of great importance as it is one of the final stages before the drug is brought to market.

The company had also acquired the drug from Eli Lilly (LLY) in 2012. This move is seen as a significant strategy to expand Vanda's product portfolio and offer innovative treatment options.